ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies $21.5 million Series A round led by current investors ...

Chris Nowers has joined natural killer (NK) cell therapy startup ONK Therapeutics as CEO. ONK disclosed the appointment of Nowers, the former head of Kite Pharma’s European operation, alongside news ...

ONK will receive non-exclusive rights to Intellia’s proprietary ex-vivo CRISPR/Cas9 technology in the development of five allogeneic NK cell therapies. Intellia Therapeutics, a gene-editing company, ...

Intellia Therapeutics, Inc. NTLA announced that it has entered into a licensing and collaboration agreement with a privately-held company, ONK Therapeutics, Inc., to develop new therapies for the ...

GALWAY, Ireland & SAN DIEGO, Calif.--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has been awarded an Innovation Partnership ...

With its breakthrough dual-targeted natural killer cell therapy platform, ONK Therapeutics is creating its own pipeline of cell therapy candidates, and seeks to further unlock its potential through ...

Serial life sciences entrepreneur Seamus Mulligan has invested in Galway company ONK Therapeutics for the second time this year alongside American biotech investor Acorn Bioventures and other ...

The NUI Galway spin-out is developing a cell therapy platform to target cancers ONK Therapeutics CEO Chris Nowers ONK Therapeutics, a Galway-based company focused on developing cell-based cancer ...

ONK has developed a process that genetically engineers natural killer cells to allow them to better pursue cancer cells that have made themselves invisible to normal natural killer (NK) cells. It is ...